Breaking News Instant updates and real-time market news.

PRTK

Paratek Pharmaceuticals

$24.95

0.9 (3.74%)

08:44
07/18/17
07/18
08:44
07/18/17
08:44

Oral only skin study represents third positive Phase 3 for Paratek, says Leerink

Leerink analyst Paul Matteis notes that Paratek Pharmaceuticals announced positive Phase 3 results from its oral only omadacycline acute bacterial skin and skin structure infection Phase 3 trial, with the study showing statistical non-inferiority on all key clinical endpoints. With three positive Phase 3s, the analyst models a 90% probability of omadacycline approval, likely by late 2018 or early 2019. Matteis reiterates an Outperform rating and $37 price target on the shares.

  • 26

    Sep

PRTK Paratek Pharmaceuticals
$24.95

0.9 (3.74%)

05/18/17
RAJA
05/18/17
INITIATION
Target $36
RAJA
Strong Buy
Paratek Pharmaceuticals initiated with a Strong Buy at Raymond James
aymond James analyst Laura Chico initiated Paratek Pharmaceuticals with a Strong Buy and a $36 price target saying omadacycline's "triple threat" potential of pneumonia, skin infections, and urinary tract, combined with management's positioning in recurrent infections and physician familiarity with tetracyclines, creates a favorable position.
06/15/17
06/15/17
NO CHANGE

Leerink 'positively inclined' ahead of Paratek data
Leerink analyst Paul Matteis says his analysis makes him optimistic that rallying 10%-20% is the most probable outcome from Paratek Pharmaceuticals' oral-only phase III skin infection results in mid-July. The company's "strong understanding" of Omadacycline pharmacokinetics, "robust efficacy" at the test-of-cure endpoint in two prior Phase IIIs and the "longstanding efficacy" of tetracyclines in skin support a "high odds of success" for the study, Matteis tells investors in a research note. The analyst reiterates an Outperform rating on Paratek with a $37 price target.
06/22/17
CANT
06/22/17
INITIATION
CANT
Overweight
Paratek Pharmaceuticals coverage assumed with an Overweight at Cantor
Cantor started coverage of Paratek with a $50 price target and an Overweight rating. The analyst recommends buying the stock ahead of what he believes will be positive data for its Omadacycline drug due out in July. The analyst thinks that the trial could show that the drug can be effectively administered through an oral-only indication for skin, differentiating it and enabling it to generate revenue that exceeds expectations.
07/18/17
HCWC
07/18/17
NO CHANGE
Target $43
HCWC
Buy
Paratek Pharmaceuticals price target raised to $43 from $36 at H.C. Wainwright
H.C. Wainwright analyst Ed Arce raised his price target for Paratek Pharmaceuticals to $43 after the company announced positive top-line results of its alloral Phase 3 trial of omadacycline for the treatment of acute bacterial skin and skin structure infections. The analyst sees higher rates of nausea and vomiting as having a negligible impact to omadacycline's commercial opportunity. He keeps a Buy rating on Paratek shares.

TODAY'S FREE FLY STORIES

AKBA

Akebia

, MACK

Merrimack

$1.30

0.02 (1.56%)

08:51
07/21/17
07/21
08:51
07/21/17
08:51
Periodicals
Former Akebia employee faces losing bail in insider trading case, Reuters says »

Schultz Chan, former…

AKBA

Akebia

MACK

Merrimack

$1.30

0.02 (1.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMC

AMC Entertainment

$20.60

0.75 (3.78%)

08:51
07/21/17
07/21
08:51
07/21/17
08:51
Initiation
AMC Entertainment initiated  »

AMC Entertainment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Aug

  • 05

    Sep

SIX

Six Flags

$56.28

-1.01 (-1.76%)

08:50
07/21/17
07/21
08:50
07/21/17
08:50
Initiation
Six Flags initiated  »

Six Flags initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

LYV

Live Nation

$36.38

-0.01 (-0.03%)

08:50
07/21/17
07/21
08:50
07/21/17
08:50
Initiation
Live Nation initiated  »

Live Nation initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNP

Union Pacific

$106.14

-1.7 (-1.58%)

08:50
07/21/17
07/21
08:50
07/21/17
08:50
Recommendations
Union Pacific analyst commentary  »

Market ignorning…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Aug

MTN

Vail Resorts

$206.11

0.09 (0.04%)

08:50
07/21/17
07/21
08:50
07/21/17
08:50
Initiation
Vail Resorts initiated  »

Vail Resorts initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GE

General Electric

$26.69

-0.25 (-0.93%)

08:49
07/21/17
07/21
08:49
07/21/17
08:49
Hot Stocks
Breaking Hot Stocks news story on General Electric »

General Electric down 3%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

  • 02

    Oct

GPC

Genuine Parts

$81.69

-1.27 (-1.53%)

08:47
07/21/17
07/21
08:47
07/21/17
08:47
Upgrade
Genuine Parts rating change  »

Genuine Parts upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLB

Schlumberger

$67.02

-0.42 (-0.62%)

08:46
07/21/17
07/21
08:46
07/21/17
08:46
Hot Stocks
Schlumberger says expects to double SPM revenue over next two years »

Says has invested $4.3B…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

GE

General Electric

$26.69

-0.25 (-0.93%)

08:45
07/21/17
07/21
08:45
07/21/17
08:45
Hot Stocks
General Electric CFO says 'trending to bottom end' of $1.60-$1.70 FY17 EPS view »

GE CFO Jeff Bornstein…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

  • 02

    Oct

ITW

Illinois Tool Works

$147.12

-0.56 (-0.38%)

08:45
07/21/17
07/21
08:45
07/21/17
08:45
Technical Analysis
Technical Earnings Preview: Illinois Tool Works in uptrend ahead of news »

The shares have been in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

XRT

S&P Retail Index SPDR

$40.59

0.09 (0.22%)

, PAA

Plains All American

$26.47

-0.16 (-0.60%)

08:45
07/21/17
07/21
08:45
07/21/17
08:45
Options
Largest borrow rate increases among liquid names »

Latest data shows the…

XRT

S&P Retail Index SPDR

$40.59

0.09 (0.22%)

PAA

Plains All American

$26.47

-0.16 (-0.60%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

  • 08

    Nov

SLB

Schlumberger

$67.02

-0.42 (-0.62%)

08:41
07/21/17
07/21
08:41
07/21/17
08:41
Hot Stocks
Schlumberger says all U.S. product lines profitable in Q2 »

Says expect high demand…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

HIMX

Himax

$8.86

0.34 (3.99%)

08:41
07/21/17
07/21
08:41
07/21/17
08:41
Downgrade
Himax rating change  »

Himax downgraded to Sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

  • 05

    Sep

SLM

Sallie Mae

$10.98

-0.83 (-7.03%)

08:41
07/21/17
07/21
08:41
07/21/17
08:41
Recommendations
Sallie Mae analyst commentary  »

Sallie Mae shares should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SLB

Schlumberger

$67.02

-0.42 (-0.62%)

08:38
07/21/17
07/21
08:38
07/21/17
08:38
Hot Stocks
Schlumberger says 'confident' in delivering free cash flow target for 2017 »

Comments from Q2 earnings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

EXPI

eXp World Holdings

$2.95

-0.04 (-1.34%)

08:36
07/21/17
07/21
08:36
07/21/17
08:36
Initiation
eXp World Holdings initiated  »

eXp World Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CXDC

China XD Plastics

$4.70

-0.025 (-0.53%)

08:35
07/21/17
07/21
08:35
07/21/17
08:35
Hot Stocks
China XD Plastics signs investment agreements for $614M in Harbin, China »

China XD Plastics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AAAP

Advanced Accelerator

$41.13

0.56 (1.38%)

08:35
07/21/17
07/21
08:35
07/21/17
08:35
Hot Stocks
Advanced Accelerator: CHMP opinion recommending approval of 177Lu oxodotreotide »

Advanced Accelerator…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FNB

F.N.B.

$13.59

-0.56 (-3.96%)

, YDKN

Acquired by FNB

08:35
07/21/17
07/21
08:35
07/21/17
08:35
Recommendations
F.N.B., Acquired by FNB analyst commentary  »

F.N.B. weakness overdone,…

FNB

F.N.B.

$13.59

-0.56 (-3.96%)

YDKN

Acquired by FNB

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OFG

OFG Bancorp

$9.85

-0.1 (-1.01%)

08:34
07/21/17
07/21
08:34
07/21/17
08:34
Earnings
OFG Bancorp reports Q2 EPS 30c, consensus 27c »

OFG Bancorp reports Q2…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Jul

ENDP

Endo

$12.32

0.24 (1.99%)

08:32
07/21/17
07/21
08:32
07/21/17
08:32
Hot Stocks
Endo closing Huntsville manufacturing and distribution facilities »

Endo will be ceasing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Aug

ADS

Alliance Data

$238.62

-24.91 (-9.45%)

08:30
07/21/17
07/21
08:30
07/21/17
08:30
Recommendations
Alliance Data analyst commentary  »

Alliance Data weakness…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 05

    Sep

KCG

KCG Holdings

, TNGO

Tangoe

08:30
07/21/17
07/21
08:30
07/21/17
08:30
Options
Two option delistings on July 21st »

Option delistings…

KCG

KCG Holdings

TNGO

Tangoe

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGEN

Repligen

$42.17

0.13 (0.31%)

08:30
07/21/17
07/21
08:30
07/21/17
08:30
Initiation
Repligen initiated  »

Repligen initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.